327 related articles for article (PubMed ID: 15176423)
1. Modulation of HERG potassium channel function by drug action.
Thomas D; Karle CA; Kiehn J
Ann Med; 2004; 36 Suppl 1():41-6. PubMed ID: 15176423
[TBL] [Abstract][Full Text] [Related]
2. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
3. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
Witchel HJ; Hancox JC
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
[TBL] [Abstract][Full Text] [Related]
4. Modulation of HERG potassium channels by extracellular magnesium and quinidine.
Po SS; Wang DW; Yang IC; Johnson JP; Nie L; Bennett PB
J Cardiovasc Pharmacol; 1999 Feb; 33(2):181-5. PubMed ID: 10028924
[TBL] [Abstract][Full Text] [Related]
5. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Spector PS; Curran ME; Keating MT; Sanguinetti MC
Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709
[TBL] [Abstract][Full Text] [Related]
6. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
[TBL] [Abstract][Full Text] [Related]
7. Facilitation of
Furutani K; Tsumoto K; Chen IS; Handa K; Yamakawa Y; Sack JT; Kurachi Y
J Gen Physiol; 2019 Feb; 151(2):214-230. PubMed ID: 30674563
[TBL] [Abstract][Full Text] [Related]
8. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
9. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
10. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
12. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of dofetilide block of HERG K+ channels.
Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
15. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.
Furutani K
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003453
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Rajamani S; Anderson CL; Anson BD; January CT
Circulation; 2002 Jun; 105(24):2830-5. PubMed ID: 12070109
[TBL] [Abstract][Full Text] [Related]
17. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Scholz EP; Zitron E; Kiesecker C; Lueck S; Kathöfer S; Thomas D; Weretka S; Peth S; Kreye VA; Schoels W; Katus HA; Kiehn J; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):404-14. PubMed ID: 14557918
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
Kiehn J; Thomas D; Karle CA; Schöls W; Kübler W
Naunyn Schmiedebergs Arch Pharmacol; 1999 Mar; 359(3):212-9. PubMed ID: 10208308
[TBL] [Abstract][Full Text] [Related]
19. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines.
Kupershmidt S; Yang IC; Hayashi K; Wei J; Chanthaphaychith S; Petersen CI; Johns DC; George AL; Roden DM; Balser JR
FASEB J; 2003 Dec; 17(15):2263-5. PubMed ID: 14525949
[TBL] [Abstract][Full Text] [Related]
20. Drug block of I(kr): model systems and relevance to human arrhythmias.
Yang T; Snyders D; Roden DM
J Cardiovasc Pharmacol; 2001 Nov; 38(5):737-44. PubMed ID: 11602820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
